Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Saved in:
Bibliographic Details
Title: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
Authors: Hurvitz SA; Fred Hutchinson Cancer Center, University of Washington, Seattle, USA., Loi S; Peter MacCallum Cancer Centre, Melbourne, Australia., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA., Okines AFC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Tolaney SM; Dana-Farber Cancer Institute, Boston, USA., Sohn J; Yonsei Cancer Center, Seoul, South Korea., Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Zhu X; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Cameron D; Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK., Bachelot T; Centre Léon Bérard, Lyon, France., Hamilton E; Sarah Cannon Research Institute, Nashville, USA., Curigliano G; European Institute of Oncology, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy., Wolff AC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, USA., Harbeck N; Breast Center, Department of OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany., Masuda N; Graduate School of Medicine, Kyoto University, Kyoto, Japan., Vahdat L; Dartmouth Health, Lebanon, USA., Zaman K; Lausanne University Hospital (CHUV), Lausanne, Switzerland., Valdes-Albini F; Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables., Block M; Nebraska Cancer Specialists, Omaha, USA., Pluard T; Saint Luke's Cancer Institute, Kansas City, USA., Tan TJ; National Cancer Centre Singapore, Singapore., Gawryletz C; University of Colorado Health, Fort Collins, USA., Chan A; Breast Cancer Research Centre, Nedlands, Australia; Curtin University, Perth, Australia., Bedard PL; Princess Margaret Hospital, University Health Network, Toronto, Canada., Yerushalmi R; Rabin Medical Center, Petah Tikva, Israel; Tel Aviv University, Tel Aviv, Israel., Xu B; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China., Schmitt M; Pfizer Inc., Bothell, USA., Xie D; Pfizer Inc., Bothell, USA., Borges VF; University of Colorado Cancer Center, Aurora, USA. Electronic address: virginia.borges@cuanschutz.edu.
Corporate Authors: HER2CLIMB-02 study investigators
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Mar; Vol. 37 (3), pp. 341-352. Date of Electronic Publication: 2025 Nov 17.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2025.11.005